Intriguingly, MUC16 has emerged as a potential target for novel cancer therapies using monoclonal antibodies or immunotherapy, particularly for ovarian and pancreatic cancer [18,19,20]. The gene discussed is MUC16; the disease is familial pancreatic carcinoma.